Chronic neutrophilic leukemia diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(10 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Chronic neutrophilic leukemia}}
{{Chronic neutrophilic leukemia}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}}
== Overview ==
== Overview ==
[[World health organization]] [[(WHO)]] introduces [[criteria]] for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the [[laboratory]] finding of [[peripheral blood cells]], [[bone marrow]], cytogenic [[mutation]], and [[differential diagnosis]].  
[[World health organization]] [[(WHO)]] introduces [[criteria]] for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the [[laboratory]] finding of [[peripheral blood cells]], [[bone marrow]], cytogenic [[mutation]], and [[differential diagnosis]].  
Line 10: Line 10:
The [[diagnosis]] of CNL is based on the [[WHO]] criteria, which include:<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>
The [[diagnosis]] of CNL is based on the [[WHO]] criteria, which include:<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>


{| class="wikitable"
{|  
|+
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |World Health Organization (WHO) Criteria for CNL diagnosis
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |World Health Organization (WHO) Criteria for CNL Diagnosis
|-
|-
! style="background: #DCDCDC; text-align: center;" |1. Peripheral blood White blood cells(WBC) ≥25 × 109/L:
! style="background: #DCDCDC; text-align: center;" |1. [[Peripheral blood]] [[White blood cells]] [[(WBC)]] ≥25 ×10<sup>9</sup>/L:
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
* Segmented neutrophils plus band forms ≥80% of WBC
* Segmented [[neutrophils]] plus [[Band cell|band]] forms ≥80% of [[WBC]]
 
* [[Neutrophil]] [[Precursor|precursors]] <10% of WBC
* Neutrophil precursors <10% of WBC
* [[Myeloblast|Myeloblasts]] rarely observed
 
* [[Monocyte]] count <1 ×10<sup>9</sup>/L
* Myeloblasts rarely observed
 
* Monocyte count <1 × 109/L
 
* No dysgranulopoies.
* No dysgranulopoies.
|-
|-
! style="background: #DCDCDC; text-align: center;" |2. Hypercellular bone marrow:
! style="background: #DCDCDC; text-align: center;" |2. Hypercellular [[bone marrow]]:
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
* Neutrophil granulocytes increased in percentage and number
* [[Neutrophil granulocytes]] increased in percentage and number
 
* Normal [[neutrophil]] [[maturation]]
* Normal neutrophil maturation
* [[Myeloblast|Myeloblasts]] <5% of [[nucleated]] cells
 
* Myeloblasts <5% of nucleated cells
 
|-
|-
! style="background: #DCDCDC; text-align: center;" |3. Not meeting WHO criteria for:
! style="background: #DCDCDC; text-align: center;" |3. Not meeting [[WHO]] criteria for:
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
* BCR-ABL1+ chronic myeloid leukemia,  
* BCR-ABL1+ [[chronic myeloid leukemia]],  
 
* [[Polycythemia vera]]
* Polycythemia vera
* [[Essential thrombocythemia]]
* Essential thrombocythemia,
* [[Primary myelofibrosis]]
* Primary myelofibrosis
|-
|-
! style="background: #DCDCDC; text-align: center;" |4.No rearrangement of:
! style="background: #DCDCDC; text-align: center;" |4. No rearrangement of:
|
| style="background: #F5F5F5;" |
* PDGFRA,
* PDGFRA  
* PDGFRB,
* [[PDGFRB]]
* FGFR1,
* [[FGFR1]]
* PCM1-JAK2
* PCM1-JAK2
|-
|-
! colspan="2" |5.Presence of CSF3RT618I or other activating CSF3R mutation or
! colspan="2" style="background: #DCDCDC; text-align: center;" |
In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia
5.Presence of CSF3RT618I or other activating [[CSF3R]] [[mutation]] or In the absence of a CSFR3R [[Mutation|mutation,]] persistent [[neutrophilia]] (at least 3 months), [[splenomegaly]], and no identifiable cause of reactive [[neutrophilia]] including the absence of a [[plasma cell neoplasm]] or, if present, demonstration of clonality of [[myeloid cells]] by [[cytogenetic]] or [[molecular]] studies.
 
including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies.
|}
|}


Line 60: Line 49:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
]
[[Category:Up-To-Date]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 20:57, 29 July 2020

Chronic neutrophilic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Chronic neutrophilic leukemia from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic neutrophilic leukemia diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic neutrophilic leukemia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic neutrophilic leukemia diagnostic study of choice

CDC on Chronic neutrophilic leukemia diagnostic study of choice

Chronic neutrophilic leukemia diagnostic study of choice in the news

Blogs on Chronic neutrophilic leukemia diagnostic study of choice

Directions to Hospitals Treating Chronic neutrophilic leukemia

Risk calculators and risk factors for Chronic neutrophilic leukemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

World health organization (WHO) introduces criteria for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the laboratory finding of peripheral blood cells, bone marrow, cytogenic mutation, and differential diagnosis.

Diagnostic Study of Choice

Study of choice

The diagnosis of CNL is based on the WHO criteria, which include:[1]

World Health Organization (WHO) Criteria for CNL diagnosis
1. Peripheral blood White blood cells (WBC) ≥25 ×109/L:
2. Hypercellular bone marrow:
3. Not meeting WHO criteria for:
4. No rearrangement of:

5.Presence of CSF3RT618I or other activating CSF3R mutation or In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies.

References

  1. Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.

Template:WH Template:WS ]